[go: up one dir, main page]

AR095206A1 - ACCELULAR VACCINE AGAINST PERTUSSIS - Google Patents

ACCELULAR VACCINE AGAINST PERTUSSIS

Info

Publication number
AR095206A1
AR095206A1 ARP140100814A ARP140100814A AR095206A1 AR 095206 A1 AR095206 A1 AR 095206A1 AR P140100814 A ARP140100814 A AR P140100814A AR P140100814 A ARP140100814 A AR P140100814A AR 095206 A1 AR095206 A1 AR 095206A1
Authority
AR
Argentina
Prior art keywords
pertussis
composition according
accelular
toxoid
vaccine against
Prior art date
Application number
ARP140100814A
Other languages
Spanish (es)
Inventor
Theunis Poolman Jan
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of AR095206A1 publication Critical patent/AR095206A1/en

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una composición de vacuna acelular contra pertussis (aP) que comprende los antígenos para Bordetella pertussis de toxoide de pertussis (PT), de hemaglutinina filamentosa (FHA) y las fimbrias tipos 2 y 3 (FIM), y opcionalmente pertactina (PRN), donde FIM está presente en una cantidad de 12 - 100 mg por dosis para humanos. Reivindicación 6: Una composición de vacuna aP de acuerdo con cualquiera de las reivindicaciones precedentes, caracterizada porque además comprende pertactina (PRN). Reivindicación 9: Una composición de acuerdo con la reivindicación 8, caracterizada porque comprende el toxoide del tétano y el toxoide de la difteria. Reivindicación 12: Una composición de acuerdo con la reivindicación 11, caracterizada porque el adyuvante comprende hidróxido de aluminio, fosfato de aluminio o una combinación de los mismos.An acellular pertussis (aP) vaccine composition comprising antigens for Bordetella pertussis of pertussis toxoid (PT), filamentous hemagglutinin (FHA) and fimbriae types 2 and 3 (FIM), and optionally pertactin (PRN), where FIM is present in an amount of 12-100 mg per dose for humans. Claim 6: An aP vaccine composition according to any of the preceding claims, characterized in that it further comprises pertactin (PRN). Claim 9: A composition according to claim 8, characterized in that it comprises tetanus toxoid and diphtheria toxoid. Claim 12: A composition according to claim 11, characterized in that the adjuvant comprises aluminum hydroxide, aluminum phosphate or a combination thereof.

ARP140100814A 2013-03-08 2014-03-10 ACCELULAR VACCINE AGAINST PERTUSSIS AR095206A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361774993P 2013-03-08 2013-03-08

Publications (1)

Publication Number Publication Date
AR095206A1 true AR095206A1 (en) 2015-09-30

Family

ID=56119030

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140100814A AR095206A1 (en) 2013-03-08 2014-03-10 ACCELULAR VACCINE AGAINST PERTUSSIS

Country Status (1)

Country Link
AR (1) AR095206A1 (en)

Similar Documents

Publication Publication Date Title
PE20151720A1 (en) ACELLULAR VACCINE AGAINST PERTUSSIS
CL2019003264A1 (en) Formulations for vaccines against neoplasia and methods for preparing the same. (divisional request 201703151)
CR11122A (en) WATER OIL EMULSION INFLUENZA VACCINE
PE20151588A1 (en) VACCINE AGAINST DENGUE VIRUS
MX2023000211A (en) Vaccine compositions having improved stability and immunogenicity.
CL2016000650A1 (en) Vaccine composition comprising an antigen and an adjuvant formulation, comprising at least 50% v / v of an oil phase, monophosphoryl lipid a (mpl-a) or an analog thereof and an immunostimulate oligonucleotide; and use of the vaccine composition to prepare a medicament.
CO6160334A2 (en) METHOD FOR THE ELABORATION OF A CONBINATION VACCINE TO PROTECT AGAINST POLIO
BR112015005056A2 (en) combination vaccines with meningococcus serogroup b and d / t / p
MX2022002106A (en) Single vial vaccine formulations.
CL2015001111A1 (en) Adjuvant composition comprising a carbohydrate attached to the chitosan forming a schiff base; vaccine formulation that comprises it; elaboration method; and use of the vaccine.
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
CO6361948A2 (en) USE OF MYCOPLASMA BOVIS ANTIGEN
MX2016016746A (en) Dual adjuvant vaccine compositions, preparation and uses.
MX2023012390A (en) Vaccination with replicon particles and oil adjuvant.
MX2016013299A (en) VACCINE COMPOSITIONS.
BR112019003992A2 (en) neisseria meningitidis vaccine
CL2013002219A1 (en) Immunogenic composition comprising bordetella bronchiseptica and an isolated pertactin antigen; and its use to treat or prevent infection by a canine respiratory pathogen in a dog.
PL404247A1 (en) LOS oligosugar Bordetella pertussis and pertussis toxin and its use in the prevention and treatment of infections caused by Bordetella pertussis
MX2017006744A (en) ADJUTIVE COMPOSITIONS AND RELATED METHODS.
BR112012014689A2 (en) vaccine composition
AR095206A1 (en) ACCELULAR VACCINE AGAINST PERTUSSIS
AR090538A1 (en) VACCINE FOR THE PREVENTION OF INFECTIONS WITH BORDETELLA
AR106501A1 (en) VACCINE ADJUSTER AND COMPOSITION CONTAINING IT
MX2020006061A (en) A VACCINE FOR PROTECTION AGAINST STREPTOCOCCUS SUIS.
MX2022000525A (en) VACCINES AGAINST EHRLICHIA AND IMMUNOGENIC COMPOSITIONS.

Legal Events

Date Code Title Description
FB Suspension of granting procedure